ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="xqfq" data-source="post: 177031" data-attributes="member: 38167"><p>I am most excited about the trials of ARBs such as Losartan. 9 clinical trials of these drugs are now starting. Here is a writeup on one at University of Minnesota: <a href="https://med.umn.edu/news-events/university-minnesota-launches-covid-19-clinical-trials-blood-pressure-drug-losartan" target="_blank">University of Minnesota Launches COVID-19 Clinical Trials of Blood Pressure Drug Losartan</a></p><p></p><p>Mechanism described a bit here: [MEDIA=youtube]1vZDVbqRhyM[/MEDIA]</p><p></p><p>This does not mean someone who is on an ARB is immune. If someone is hypertensive and takes an ARB, then they are more or less at 'baseline' with respect to total number of unblocked AT1 receptors. I speculate they may require an additional ARB (e.g. if losartan proves effective, then add losartan twice a day), with twice-daily dosing.</p><p></p><p>It's possible this may not work, but I give it a 70% chance of working to stop the severity of the disease. The anti-viral approaches such as hydroxychloroquine and others would, I suspect, require treatment very early in the infection to show efficacy. For most people that is not possible. This is especially true of drugs like Remdesivir which require IV administration.</p><p></p><p>Convalescent plasma almost certainly works. The barrier to this treatment is logistics and competence of organizations, which is lacking in the US. Mass testing, including antibody testing, and plasma collection efforts should have started a month ago, but are still in very early stages. We can reduce the likelihood of death significantly by ensuring we have enough plasma on hand. If the majority of people (>= 80%) do not require hospitalization, those people can all donate plasma. Then we can give the plasma to the 20% requiring hospitalization. A previously infected person can donate plasma at least once every 28 days and likely more often than that. A given donation can save the lives of 2-4 people. If you do the math, it's clear that this method, if scaled up, can significantly reduce the risk of death if enough plasma is collected and deployed quickly.</p><p></p><p>Plasma can also be given prophylactically to healthcare workers and will likely be protective for a number of weeks. Less plasma may be required in these cases, too.</p></blockquote><p></p>
[QUOTE="xqfq, post: 177031, member: 38167"] I am most excited about the trials of ARBs such as Losartan. 9 clinical trials of these drugs are now starting. Here is a writeup on one at University of Minnesota: [URL='https://med.umn.edu/news-events/university-minnesota-launches-covid-19-clinical-trials-blood-pressure-drug-losartan']University of Minnesota Launches COVID-19 Clinical Trials of Blood Pressure Drug Losartan[/URL] Mechanism described a bit here: [MEDIA=youtube]1vZDVbqRhyM[/MEDIA] This does not mean someone who is on an ARB is immune. If someone is hypertensive and takes an ARB, then they are more or less at 'baseline' with respect to total number of unblocked AT1 receptors. I speculate they may require an additional ARB (e.g. if losartan proves effective, then add losartan twice a day), with twice-daily dosing. It's possible this may not work, but I give it a 70% chance of working to stop the severity of the disease. The anti-viral approaches such as hydroxychloroquine and others would, I suspect, require treatment very early in the infection to show efficacy. For most people that is not possible. This is especially true of drugs like Remdesivir which require IV administration. Convalescent plasma almost certainly works. The barrier to this treatment is logistics and competence of organizations, which is lacking in the US. Mass testing, including antibody testing, and plasma collection efforts should have started a month ago, but are still in very early stages. We can reduce the likelihood of death significantly by ensuring we have enough plasma on hand. If the majority of people (>= 80%) do not require hospitalization, those people can all donate plasma. Then we can give the plasma to the 20% requiring hospitalization. A previously infected person can donate plasma at least once every 28 days and likely more often than that. A given donation can save the lives of 2-4 people. If you do the math, it's clear that this method, if scaled up, can significantly reduce the risk of death if enough plasma is collected and deployed quickly. Plasma can also be given prophylactically to healthcare workers and will likely be protective for a number of weeks. Less plasma may be required in these cases, too. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Coronavirus COVID-19 Update: Hydroxychloroquine and Other Treatments
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top